Pharmaceuticals company Alivus Life Sciences announced Q2FY26 results For Q2FY26, Alivus registered a Revenue from operations of Rs 5,880 million, a growth of 16.0% YoY. For Q2FY26, EBITDA was at Rs 1,939 million, a growth of 35.7% YoY. EBITDA margins were at 33.0%, up 480 bps YoY. PAT for Q2FY26 stood at Rs 1,301 million, a growth of 36.5% YoY and PAT margins were at 22.1%, up 330 bps YoY. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: “Our performance, this quarter, was fuelled by strong momentum in the non-GPL business, which delivered an impressive 39.7% YoY growth. Non-GPL business has shown a robust performance over last four quarters, driven by healthy demand across key geographies including ROW, LATAM, Japan, Europe, and India, all of which contributed meaningfully to the overall performance. As we look forward, we remain confident of delivering a stronger performance in second half. This outlook is supported by continued robustness in non-GPL business and a better visibility on GPL business. Moreover, a continued ramp-up of our CDMO projects gives us confidence in the overall growth of our business. We remain confident of maintaining margins at around 30%, despite the absence of PLI benefits. The margins are reinforced by a robust pipeline of new launches and operational efficiencies.” Tushar Mistry, CFO, Alivus Life Sciences, said: “At Alivus Life Sciences, we delivered a strong revenue growth of 16% in Q2FY26. During the quarter, gross and EBITDA margins were at 57.7% and 33% respectively, at the upper end of our guided ranges of above 55% and 30%, supported by a favourable product mix, successful new launches, and continued cost efficiency. Notably, we maintained margins beyond our guidance even without the PLI scheme benefits, reflecting the robustness in our operations. The Company generated strong cash flow from operations of Rs 148 crore in Q2FY26, with cash & cash equivalents of Rs 653 crore on the books as of 30th September 2025, providing ample support for our ongoing growth plans and allowing us to sustain a healthy, debt-free balance sheet.” Result PDF